XPB1 Antibody

What is XBP1 and what is its significance in cellular biology?

XBP1 (X-box binding protein 1) is a member of the BZIP protein family that functions as a transcription factor during endoplasmic reticulum (ER) stress by regulating the unfolded protein response (UPR). It was initially identified as a key transcriptional regulator of major histocompatibility complex (MHC) class II in B cells in the early 1990s . In humans, the canonical protein has a reported length of 261 amino acids with a mass of approximately 28.7 kDa . XBP1 is a critical component of the IRE1α-XBP1 signaling pathway, which represents the most conserved branch among the three UPR pathways .

The protein plays essential roles in diverse biological processes, including hepatocyte growth, plasma cell differentiation, immunoglobulin secretion, and most notably, the cellular response to unfolded proteins . Its biological significance extends to embryonic development, as XBP1 deletion in embryos is lethal due to failure of fetal liver development . In normal physiology, XBP1 is ubiquitously expressed in adult mice, with preferential expression in liver, exocrine glands, osteoblasts, chondroblasts, brown fat, and whisker follicles during mouse embryogenesis .

What are the different isoforms of XBP1 and what distinguishes them?

XBP1 exists in two major isoforms resulting from alternative splicing:

• Unspliced XBP1 (XBP1u or XBP1-U): This is the initial form of the protein translated from unspliced mRNA. XBP1u lacks the transactivation domain necessary for efficient activation of the unfolded protein response .

• Spliced XBP1 (XBP1s or XBP1-S): During ER stress, IRE1α (Inositol-requiring enzyme 1α) becomes activated and functions as an endoribonuclease to excise an intron from XBP1 mRNA. This splicing event results in a frameshift, producing a longer 371 amino acid protein containing a transactivation domain . XBP1s is then translocated to the nucleus where it binds to regulatory elements of downstream genes to activate the UPR efficiently .

The fundamental distinction between these isoforms lies in their functional capacity - only the spliced form of XBP1 can efficiently activate the UPR and function as a potent transcriptional activator . This splicing-dependent activation represents a critical regulatory mechanism in the cellular stress response.

What experimental applications are XBP1 antibodies commonly used for?

XBP1 antibodies are utilized across multiple experimental applications in research settings:

• Western blot (WB): For detecting and quantifying XBP1 protein levels in cell or tissue lysates. According to product specifications, optimal antibody concentrations typically range from 1-2 μg/mL .

• Immunohistochemistry (IHC): For visualizing XBP1 expression and localization in tissue sections, particularly useful for examining expression patterns in clinical samples and animal models. Both paraffin-embedded (IHC-p) and frozen (IHC-fr) sections can be analyzed .

• Immunocytochemistry (ICC): For studying the subcellular localization of XBP1 in cultured cells, with recommended starting concentrations around 2 μg/mL .

• Immunofluorescence (IF): For detailed visualization of XBP1 localization, often used to determine nuclear translocation during ER stress, with typical starting concentrations of 2-4 μg/mL .

• Flow cytometry (FCM): For quantitative analysis of XBP1 expression at the single-cell level .

• ELISA: For quantitative measurement of XBP1 in solution .

These applications enable researchers to investigate XBP1's expression, localization, and functional roles in various biological contexts and disease states.

How does XBP1 contribute to cancer biology and progression?

XBP1, particularly in its spliced form (XBP1s), plays multifaceted roles in cancer biology through several mechanisms:

• Cell proliferation and survival: Gene expression profiling studies indicate that XBP1s regulates BCL-2 and several other genes related to cell cycles and apoptosis . XBP1's regulatory activity in these processes promotes cell survival, contributing to tumorigenesis and tumor progression .

• Oncogenic pathway activation: XBP1 can activate multiple oncogenic signaling pathways, including NF-κB, AP-1, and Myc . A genome-wide siRNA screening identified 162 genes involved in regulating XBP1 splicing and UPR in breast cancer, highlighting the extensive network of XBP1-mediated effects .

• Nuclear expression correlation with outcomes: The expression of XBP1s in the nuclei is significantly associated with poor clinical survival in cancer patients, while no relationship has been found between cytoplasmic XBP1s and survival .

• Carcinogenesis capacity: Cells with XBP1-deficiency show significantly decreased ability for carcinogenesis in nude mice models, demonstrating its importance in tumor formation .

• Stress adaptation: Cancer cells exist in stressful microenvironments (hypoxia, nutrient deprivation, metabolic dysfunction), leading to continuous ER stress. XBP1 helps cancer cells adapt to these conditions through its role in the UPR .

Research suggests that XBP1's diverse transcriptional targets, especially those involved in cell survival, make it a significant contributor to cancer development and progression, with potential implications for therapeutic interventions.

What is the relationship between XBP1 and the unfolded protein response (UPR) in experimental models?

XBP1 represents a critical component of the IRE1α branch of the UPR, which is the most evolutionarily conserved of the three UPR pathways . This relationship is characterized by:

• Stress sensing and activation: During ER stress, IRE1α becomes activated and functions as an endoribonuclease to splice XBP1 mRNA. This splicing removes a 26-nucleotide intron, resulting in a frameshift that generates XBP1s with a transactivation domain .

• Transcriptional regulation: Once produced, XBP1s translocates to the nucleus and binds to specific DNA elements, including the UPR element (UPRE) and CRE-like elements with the consensus sequence 5'-GATGACGTG[TG]N(3)[AT]T-3' . XBP1s also binds to some TPA response elements (TRE) and the HLA DR-alpha promoter .

• Target gene activation: As a transcription factor, XBP1s regulates numerous genes involved in protein folding, ER-associated degradation (ERAD), protein synthesis, and lipid biosynthesis . It coordinates with other UPR transcription factors like ATF6 to stimulate the production of ER stress proteins, including the ER resident protein chaperones glucose regulated protein (GRP) 78 and GRP94 .

• XBP1-FKBP13 axis: FK506-binding protein 13 (FKBP13), a downstream factor of XBP1, interacts with surplus Ig molecules or misfolded proteins to direct them to the ubiquitin-dependent degradation system in plasma cells, ameliorating ER stress .

In experimental models, disruption of XBP1 function typically results in heightened ER stress and decreased cellular ability to cope with protein folding challenges, particularly in secretory cells with high protein production demands.

How can researchers differentiate between the spliced and unspliced forms of XBP1?

Differentiating between XBP1u (unspliced) and XBP1s (spliced) forms is crucial for understanding UPR activation status. Researchers can employ several methodological approaches:

• PCR-based detection:

  • RT-PCR followed by restriction enzyme digestion: The spliced form loses a PstI restriction site, allowing for discrimination between the two forms.

  • Specific primers can be designed to amplify either spliced or unspliced forms selectively.

• Protein-based detection with antibodies:

  • Isoform-specific antibodies: Some antibodies are specifically designed to recognize epitopes unique to either the spliced or unspliced form. Researchers should carefully review antibody specifications to determine isoform specificity .

  • Size-based discrimination: The spliced form (XBP1s) has a molecular weight of approximately 40 kDa (371 amino acids), while the unspliced form (XBP1u) is around 29 kDa (261 amino acids) . This size difference can be resolved by SDS-PAGE and Western blotting.

  • Subcellular localization: XBP1s predominantly localizes to the nucleus due to its function as a transcription factor, while XBP1u is mainly cytoplasmic. Immunofluorescence or cell fractionation followed by Western blotting can exploit this difference .

• Functional assays:

  • Reporter assays using XBP1s-responsive promoters can indirectly indicate the presence of active XBP1s.

  • Analyzing downstream target gene expression as XBP1s activates specific sets of UPR-related genes.

When interpreting results, researchers should be aware that the ratio between spliced and unspliced forms, rather than absolute amounts, often provides the most informative indicator of UPR activation status in the experimental system.

What are the optimal conditions for using XBP1 antibodies in Western blotting?

For optimal Western blot results with XBP1 antibodies, researchers should consider the following protocol parameters:

• Sample preparation:

  • Nuclear and cytoplasmic fractionation may be beneficial to enrich for XBP1s (predominantly nuclear) versus XBP1u (predominantly cytoplasmic) .

  • Include protease inhibitors in lysis buffers to prevent degradation.

  • For detecting both isoforms, whole cell lysates prepared with denaturing buffers containing SDS work effectively.

• Antibody selection and concentration:

  • Based on product specifications, optimal antibody concentrations typically range from 1-2 μg/mL for Western blotting .

  • Consider whether detecting both isoforms or specific isoforms is required for the research question.

• Gel electrophoresis conditions:

  • Use 10-12% SDS-PAGE gels for optimal resolution of both XBP1 isoforms.

  • Ensure adequate run time to separate the 29 kDa (XBP1u) and 40 kDa (XBP1s) bands effectively.

• Transfer conditions:

  • Semi-dry or wet transfer systems are both suitable.

  • Transfer time and voltage should be optimized based on protein size and equipment specifications.

• Blocking and antibody incubation:

  • Typically, 5% non-fat dry milk or BSA in TBST is effective for blocking.

  • Primary antibody incubation can be performed overnight at 4°C or for 2 hours at room temperature.

  • Secondary antibody selection should match the host species of the primary antibody.

• Detection system:

  • Both chemiluminescence and fluorescence-based detection systems are compatible.

  • For quantitative analysis, consider using fluorescence-based systems that offer better linearity.

• Controls:

  • Positive controls: Recombinant XBP1 protein (100 ng has been reported as effective) or lysates from cells treated with known ER stress inducers like tunicamycin or thapsigargin.

  • Negative controls: Lysates from XBP1 knockdown cells if available.

Researchers should optimize these conditions based on their specific experimental system and antibody characteristics to achieve reliable and reproducible results.

What protocols are recommended for immunocytochemistry and immunofluorescence with XBP1 antibodies?

For effective immunocytochemistry (ICC) and immunofluorescence (IF) using XBP1 antibodies, researchers should consider the following protocol guidelines:

• Cell preparation and fixation:

  • Grow cells on appropriate coverslips or chamber slides.

  • Fixation with 4% paraformaldehyde (10-15 minutes at room temperature) preserves protein antigenicity and cellular architecture.

  • For some applications, methanol fixation (-20°C for 10 minutes) may be preferred, especially for nuclear proteins.

• Permeabilization:

  • Use 0.1-0.5% Triton X-100 in PBS for 5-10 minutes to allow antibody access to intracellular antigens.

  • For more gentle permeabilization, 0.1-0.5% saponin may be used.

• Blocking:

  • Block with 5-10% normal serum (from the species of the secondary antibody) for 30-60 minutes.

  • Addition of 0.1-0.3% Triton X-100 to the blocking solution can improve antibody penetration.

• Primary antibody incubation:

  • For ICC, start with XBP1 antibody at 2 μg/mL as recommended in the product specifications .

  • For IF, start with 4 μg/mL, though optimization may be necessary .

  • Incubate either for 1-2 hours at room temperature or overnight at 4°C.

• Secondary antibody incubation:

  • Use fluorophore-conjugated secondary antibody matching the host species of primary antibody.

  • Incubate for 1 hour at room temperature, protected from light.

  • Include DAPI or other nuclear counterstain for nuclear localization studies.

• Mounting and visualization:

  • Mount with anti-fade mounting medium to preserve fluorescence.

  • Analyze using appropriate microscopy (confocal microscopy is particularly useful for co-localization studies).

• Controls and validation:

  • Include cells treated with ER stress inducers as positive controls for XBP1 activation.

  • Use cells with XBP1 knockdown or knockout as negative controls when available.

  • Consider dual staining with ER markers for co-localization studies.

• Special considerations:

  • For studying XBP1 activation, treat cells with ER stress inducers like tunicamycin, thapsigargin, or DTT.

  • Monitor nuclear translocation of XBP1s as an indicator of UPR activation.

  • HepG2 cells have been successfully used for XBP1 immunocytochemistry and immunofluorescence studies .

These protocols should be optimized according to specific cell types, antibodies, and research questions for optimal signal-to-noise ratio and specificity.

How can researchers validate the specificity of XBP1 antibodies?

Validating antibody specificity is crucial for ensuring reliable experimental results. For XBP1 antibodies, researchers should consider these validation approaches:

• Genetic validation:

  • Compare staining patterns in XBP1 wild-type versus knockout/knockdown cells or tissues.

  • Use siRNA or CRISPR/Cas9 systems to create XBP1-deficient controls.

  • Genetic validation provides the most definitive evidence for antibody specificity.

• Recombinant protein controls:

  • Perform Western blot with purified recombinant XBP1 protein to confirm the antibody detects the correct molecular weight band .

  • Consider testing against both XBP1s and XBP1u recombinant proteins if available.

• Peptide competition assays:

  • Pre-incubate the antibody with a blocking peptide containing the epitope.

  • A specific antibody will show diminished or absent signal when pre-blocked with its cognate peptide.

• Multiple antibody comparison:

  • Compare staining patterns using antibodies from different sources or those targeting different epitopes of XBP1.

  • Consistent patterns with different antibodies increase confidence in specificity.

• Physiological validation:

  • Confirm expected changes in XBP1 expression or localization under known physiological conditions.

  • For example, treatment with ER stress inducers should increase XBP1s levels and nuclear localization .

• Cross-reactivity testing:

  • Test the antibody across multiple species if cross-reactivity is claimed (human, mouse, rat are common for XBP1 antibodies) .

  • Verify the antibody does not cross-react with closely related proteins.

• Application-specific validation:

  • Validate separately for each application (WB, IHC, ICC, etc.) as specificity can vary across techniques.

  • For IHC/ICC, include isotype controls to assess non-specific binding.

• Batch-to-batch consistency:

  • When receiving new antibody lots, perform comparative testing with previous lots.

  • Document lot numbers used in experiments to track potential variability.

These validation steps ensure that experimental observations truly reflect XBP1 biology rather than artifacts from non-specific antibody interactions.

What are common issues when working with XBP1 antibodies and how can they be resolved?

Researchers frequently encounter several challenges when working with XBP1 antibodies. Here are common issues and their potential solutions:

• Poor detection of XBP1s:

  • Issue: The spliced form (XBP1s) may be difficult to detect under basal conditions.

  • Solution: Treat cells with ER stress inducers (tunicamycin, thapsigargin, DTT) to increase XBP1 splicing and enhance detection .

  • Solution: For Western blots, optimize gel percentage (10-12%) to better resolve the distinct XBP1 isoforms.

• Non-specific bands in Western blots:

  • Issue: Multiple bands appearing at unexpected molecular weights.

  • Solution: Increase blocking time/concentration and optimize antibody dilution.

  • Solution: Use freshly prepared lysates with complete protease inhibitor cocktails to prevent degradation products.

  • Solution: Validate bands using XBP1 knockdown/knockout controls to identify specific signals.

• High background in immunostaining:

  • Issue: Diffuse staining making it difficult to interpret specific signals.

  • Solution: Optimize blocking conditions (time, blocking agent, concentration).

  • Solution: Titrate antibody concentration; start with 2 μg/mL for ICC and 4 μg/mL for IF as recommended .

  • Solution: Increase washing steps' duration and number after antibody incubations.

• Inconsistent results between experiments:

  • Issue: Variable staining patterns or band intensities across repeat experiments.

  • Solution: Standardize cell culture conditions, as XBP1 expression is sensitive to cellular stress.

  • Solution: Document lot numbers of antibodies and validate new lots against previous ones.

  • Solution: Establish consistent positive controls for each experiment (e.g., cells treated with known ER stressors).

• Difficulty differentiating nuclear from cytoplasmic staining:

  • Issue: Unclear subcellular localization of XBP1.

  • Solution: Use confocal microscopy rather than widefield for better resolution of subcellular compartments.

  • Solution: Perform nuclear/cytoplasmic fractionation for Western blot analysis to complement imaging data.

  • Solution: Co-stain with nuclear markers like DAPI and specific organelle markers.

• Cross-reactivity with related proteins:

  • Issue: Antibody detecting proteins beyond XBP1.

  • Solution: Perform peptide competition assays to confirm specificity.

  • Solution: Validate using genetic approaches (siRNA, CRISPR) to confirm signal reduction with XBP1 depletion.

• Weak signal in specific cell types:

  • Issue: Poor detection in certain cells despite known XBP1 expression.

  • Solution: Optimize fixation conditions, as some fixatives may mask epitopes.

  • Solution: Consider epitope retrieval methods for IHC/ICC applications.

  • Solution: Test alternative antibodies targeting different epitopes of XBP1.

These troubleshooting approaches should be systematically implemented and documented to establish reliable protocols for XBP1 detection in specific experimental contexts.

How should researchers interpret XBP1 expression patterns in relation to the unfolded protein response activation?

Interpreting XBP1 expression patterns requires consideration of several factors to accurately assess UPR activation status:

• XBP1 isoform ratio analysis:

  • The ratio of XBP1s to XBP1u is often more informative than absolute levels of either isoform.

  • Increased XBP1s:XBP1u ratio indicates active IRE1α signaling and UPR activation .

  • Both isoforms should be quantified when possible, using Western blot or PCR-based approaches.

• Subcellular localization assessment:

  • Nuclear accumulation of XBP1s strongly indicates active UPR signaling .

  • Cytoplasmic XBP1s may not correlate with clinical outcomes or functional activation .

  • Nuclear/cytoplasmic fractionation followed by Western blot or immunofluorescence microscopy provides critical localization data.

• Temporal dynamics:

  • XBP1 splicing occurs rapidly (within hours) after UPR induction and may return to baseline despite continued stress.

  • Time-course experiments are essential to capture the dynamic nature of the response.

  • Both acute and chronic stress conditions should be examined when relevant to the research question.

• Correlation with downstream targets:

  • Expression of known XBP1s target genes (e.g., EDEM1, PDI, BiP/GRP78) should be assessed as functional validation.

  • Chaperone induction (particularly GRP78 and GRP94) serves as confirmation of functional XBP1s activity .

  • The XBP1-FKBP13 axis can be examined as a downstream effect of XBP1 activation .

• Multi-pathway analysis:

  • XBP1/IRE1α represents only one branch of the UPR; parallel assessment of PERK and ATF6 pathways provides context.

  • XBP1 is up-regulated by ATF6 through direct binding to the ERSE in response to ER stress .

  • Integrated analysis of all three UPR branches gives a comprehensive picture of cellular stress status.

• Context-specific considerations:

  • Baseline XBP1 expression varies significantly between tissue and cell types.

  • In plasma cells and other secretory cells, constitutive XBP1s expression may be normal rather than indicative of stress .

  • Cancer cells often show altered baseline UPR activation, requiring careful interpretation of "normal" vs. "stressed" states .

• Clinical correlation:

  • Nuclear XBP1s expression has been associated with poor clinical outcomes in cancer patients .

  • When examining patient samples, correlate XBP1 expression patterns with clinical data when available.

These interpretative frameworks help researchers move beyond simple detection to meaningful functional insights about UPR activation status and its biological implications.

What controls should be included when using XBP1 antibodies in experimental settings?

Proper experimental controls are essential for reliable and interpretable results when working with XBP1 antibodies. Researchers should include the following controls:

• Positive controls:

  • Cells treated with known ER stress inducers:

    • Tunicamycin (inhibits N-linked glycosylation)

    • Thapsigargin (disrupts calcium homeostasis)

    • DTT (disrupts disulfide bonds)

    • Glucose deprivation

  • Recombinant XBP1 protein (100 ng has been reported as effective for Western blot)

  • Cell lines with constitutively high XBP1 expression (e.g., plasma cells or certain cancer cell lines)

• Negative controls:

  • Genetic controls: Cells with XBP1 knockdown or knockout

  • Antibody controls: Isotype control antibodies to assess non-specific binding

  • Pre-immune serum controls for polyclonal antibodies

  • Primary antibody omission controls

• Specificity controls:

  • Peptide competition assays using the immunizing peptide

  • Multiple antibodies targeting different epitopes of XBP1

  • Testing in multiple cell lines with variable XBP1 expression levels

• Application-specific controls:

  • For Western blot:

    • Molecular weight markers to confirm expected sizes (29 kDa for XBP1u, 40 kDa for XBP1s)

    • Loading controls (β-actin, GAPDH, or histone H3 for nuclear fractions)

    • Subcellular fractionation quality controls (e.g., GAPDH for cytoplasm, lamin for nucleus)

  • For IHC/ICC/IF:

    • Autofluorescence controls (untreated samples)

    • Secondary antibody-only controls

    • Counterstains for subcellular localization (e.g., DAPI for nucleus, ER-Tracker for ER)

• Biological context controls:

  • Time course experiments to capture dynamic changes in XBP1 splicing

  • Dose-response experiments with ER stress inducers

  • Recovery experiments (stress induction followed by recovery period)

  • Correlation with other UPR markers (BiP/GRP78, phospho-PERK, ATF6 cleavage)

• Technical controls:

  • Inter-assay calibration samples for quantitative comparisons across experiments

  • Batch controls when analyzing multiple samples over time

  • Inter-observer controls for subjective assessments (e.g., immunostaining intensity scoring)

• Species-specific controls:

  • When studying cross-species reactions, include samples from each species claimed in the antibody specifications (human, mouse, rat)

These controls should be systematically incorporated into experimental designs to ensure robust, reproducible, and meaningful results when studying XBP1 biology.

What future directions exist for XBP1 antibody applications in research?

XBP1 antibody technology continues to evolve, with several promising future directions for research applications:

• Advanced isoform-specific detection: Development of highly specific antibodies that can selectively detect XBP1s and XBP1u with increased sensitivity would enhance our ability to monitor UPR activation states with greater precision . These tools could facilitate more nuanced understanding of the temporal dynamics of XBP1 splicing under various stress conditions.

• Post-translational modification mapping: As the search results indicate, XBP1 undergoes various post-translational modifications including ubiquitination, acetylation, and protein cleavage . Antibodies specifically recognizing these modifications would enable researchers to understand how they impact XBP1 function and regulation under different physiological and pathological conditions.

• Single-cell applications: Adaptation of XBP1 antibodies for single-cell technologies, including mass cytometry (CyTOF) and imaging mass cytometry, would allow for more sophisticated analysis of UPR heterogeneity within complex tissues and tumor microenvironments . This could reveal previously unrecognized cell populations with distinct UPR activation profiles.

• Therapeutic monitoring: As XBP1-targeted therapies and XBP1 peptide-based vaccinations emerge for cancer treatment, antibodies will play crucial roles in monitoring treatment efficacy and patient selection . Developing standardized immunoassays for clinical applications represents an important translational direction.

• Multiplex imaging approaches: Integration of XBP1 antibodies into multiplexed immunofluorescence panels would enable simultaneous visualization of UPR activation alongside other cancer-related pathways, immune cell markers, and microenvironmental features . This could provide unprecedented insights into the complex interplay between ER stress and tumor biology.

• Dynamic in vivo imaging: Development of techniques to monitor XBP1 activation in living systems, potentially through antibody-based biosensors or reporter systems coupled with antibody validation, would transform our understanding of UPR dynamics in complex physiological contexts.

These advances will require continued refinement of antibody specificity, sensitivity, and validation across multiple experimental systems. As our understanding of XBP1 biology expands, so too will the sophisticated applications of antibodies targeting this critical stress response regulator.

How does understanding XBP1 biology inform experimental design considerations?

A comprehensive understanding of XBP1 biology should fundamentally shape experimental approaches when investigating this protein:

• Temporal considerations: XBP1 splicing occurs dynamically, with rapid activation followed by potential adaptation. Experimental designs should incorporate appropriate time points (minutes to hours after stress induction) to capture these dynamics . Single time-point experiments may miss critical phases of XBP1 activation or resolution.

• Microenvironmental factors: As cancer cells experience variable stresses depending on their microenvironment (hypoxia, nutrient limitation, etc.), experimental conditions should recapitulate relevant microenvironmental features . Three-dimensional culture systems, co-cultures, or controlled nutrient/oxygen conditions may provide more physiologically relevant contexts than standard culture conditions.

• Cell type-specific regulation: XBP1 has distinct roles in different cell types, with particularly important functions in secretory cells and immune populations. Cell type selection should be informed by these biological differences, and generalizations across cell types should be made cautiously .

• Multi-pathway analysis: XBP1 functions within the broader context of the integrated stress response. Experiments should consider parallel assessment of other UPR branches (PERK, ATF6) and related stress pathways to develop comprehensive models of cellular stress responses .

• Translational relevance: XBP1's implications in cancer progression suggest that experimental designs should incorporate clinically relevant models and endpoints. Patient-derived xenografts, organoids, or analysis of patient samples alongside mechanistic studies can enhance translational significance .

• Functional readouts: Beyond measuring XBP1 expression or splicing, experiments should assess functional outcomes of XBP1 activity, including downstream target gene expression, cell survival under stress conditions, and phenotypic responses like proliferation or metastatic capacity .

• Genetic approaches: Given XBP1's complex regulation and multiple isoforms, genetic manipulation approaches (conditional knockouts, splicing-specific mutations) provide powerful tools for dissecting specific aspects of XBP1 function. These should complement antibody-based detection methods for comprehensive analysis.